Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.

Schito, M; Migliori, GB; Fletcher, HA; McNerney, R; Centis, R; D'Ambrosio, L; Bates, M; Kibiki, G; Kapata, N; Corrah, T; Bomanji, J; Vilaplana, C; Johnson, D; Mwaba, P; Maeurer, M; Zumla, A; (2015) Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clinical infectious diseases, 61 (suppl 3). S102-S118. ISSN 1058-4838 DOI:

Full text not available from this repository.


Despite concerted efforts over the past 2 decades at developing new diagnostics, drugs, and vaccines with expanding pipelines, tuberculosis remains a global emergency. Several novel diagnostic technologies show promise of better point-of-care rapid tests for tuberculosis including nucleic acid-based amplification tests, imaging, and breath analysis of volatile organic compounds. Advances in new and repurposed drugs for use in multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis have focused on development of several new drug regimens and their evaluation in clinical trials and now influence World Health Organization guidelines. Since the failure of the MVA85A vaccine 2 years ago, there have been no new tuberculosis vaccine candidates entering clinical testing. The current status quo of the lengthy treatment duration and poor treatment outcomes associated with MDR/XDR tuberculosis and with comorbidity of tuberculosis with human immunodeficiency virus and noncommunicable diseases is unacceptable. New innovations and political and funder commitment for early rapid diagnosis, shortening duration of therapy, improving treatment outcomes, and prevention are urgently required.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Research Centre: TB Centre
PubMed ID: 26409271
Web of Science ID: 362952900002


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item